Continued asciminib treatment for certain leukemia patients
Part of Blood & lymphatic, Cancer clinical trials.
This trial lets people who already have Philadelphia chromosome–positive (Ph+) leukemia and are benefiting from asciminib (or certain related medicines) continue treatment. It mainly tests whether ongoing care in a follow-on study is safe and workable for participants.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You currently have Ph+ CML or Ph+ ALL and you are already taking asciminib as part of a Novartis study.
- You may be taking asciminib alone or with common leukemia medicines such as imatinib, nilotinib, or dasatinib, or you may be on imatinib/nilotinib/bosutinib as your current treatment.
- Your earlier (parent) study treatment is still active—you were not stopped from the parent study.
- You must have handled side effects well: any side effects that were possibly caused by the study medicine must be resolved.
- You must be able and willing to follow the study schedule and treatment plan for visits and procedures.
- You must follow pregnancy-prevention rules during the study (not pregnant or nursing, and using highly effective contraception if you could become pregnant or father a child).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication called asciminib in children and teens with a type of leukemia called Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It aims to see if the drug is safe and effective for patients who are newly diagnosed or whose current treatment has stopped working or caused side effects.
This study tests how well asciminib works and how safe it is for people with a type of blood cancer called chronic myeloid leukemia (CML). It helps see if asciminib is a good option compared to other standard treatments.
This trial tests a new drug called asciminib given after a stem cell transplant to prevent the return of a type of leukemia. If you have Philadelphia chromosome-positive B-ALL or blast-phase CML, this may help keep you in remission.
This trial tests an experimental drug called asciminib for children and young adults whose leukemia (a specific type of B-cell acute lymphoblastic leukemia with certain gene changes) has come back or not responded to treatment. The goal is to see if the drug is safe and effective for these patients.
This study tests a targeted pill called asciminib for people newly diagnosed with chronic-phase CML. It aims to see if this drug is safe and effective as an early treatment option.
This trial tests the drug asciminib after a stem cell transplant or CAR T-cell therapy for adults with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) to help prevent the cancer from coming back.
Hear when a new Chronic Myelogenous Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.